Literature DB >> 27391789

Hypoxia Responsive, Tumor Penetrating Lipid Nanoparticles for Delivery of Chemotherapeutics to Pancreatic Cancer Cell Spheroids.

Prajakta Kulkarni, Manas K Haldar, Preeya Katti1, Courtney Dawes2, Seungyong You, Yongki Choi, Sanku Mallik.   

Abstract

Solid tumors are often poorly irrigated due to structurally compromised microcirculation. Uncontrolled multiplication of cancer cells, insufficient blood flow, and the lack of enough oxygen and nutrients lead to the development of hypoxic regions in the tumor tissues. As the partial pressure of oxygen drops below the necessary level (10 psi), the cancer cells modulate their genetic makeup to survive. Hypoxia triggers tumor progression by enhancing angiogenesis, cancer stem cell production, remodeling of the extracellular matrix, and epigenetic changes in the cancer cells. However, the hypoxic regions are usually located deep in the tumors and are usually inaccessible to the intravenously injected drug carrier or the drug. Considering the designs of the reported nanoparticles, it is likely that the drug is delivered to the peripheral tumor tissues, close to the blood vessels. In this study, we prepared lipid nanoparticles (LNs) comprising the synthesized hypoxia-responsive lipid and a peptide-lipid conjugate. We observed that the resultant LNs penetrated to the hypoxic regions of the tumors. Under low oxygen partial pressure, the hypoxia-responsive lipid undergoes reduction, destabilizing the lipid membrane, and releasing encapsulated drugs from the nanoparticles. We demonstrated the results employing spheroidal cultures of the pancreatic cancer cells BxPC-3. We observed that the peptide-decorated, drug encapsulated LNs reduced the viability of pancreatic cancer cells of the spheroids to 35% under hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27391789      PMCID: PMC5502747          DOI: 10.1021/acs.bioconjchem.6b00241

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  21 in total

1.  A simple procedure for the isolation of rat liver microsomes.

Authors:  S A. Kamath; F A. Kummerow; K Ananth Narayan
Journal:  FEBS Lett       Date:  1971-09-15       Impact factor: 4.124

Review 2.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Hypoxia-sensitive fluorescent probes for in vivo real-time fluorescence imaging of acute ischemia.

Authors:  Kazuki Kiyose; Kenjiro Hanaoka; Daihi Oushiki; Tomomi Nakamura; Mayumi Kajimura; Makoto Suematsu; Hiroaki Nishimatsu; Takehiro Yamane; Takuya Terai; Yasunobu Hirata; Tetsuo Nagano
Journal:  J Am Chem Soc       Date:  2010-10-27       Impact factor: 15.419

Review 4.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

Review 5.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.

Authors:  Fabienne Danhier; Olivier Feron; Véronique Préat
Journal:  J Control Release       Date:  2010-08-24       Impact factor: 9.776

6.  Hypoxia-targeted siRNA delivery.

Authors:  F Perche; S Biswas; T Wang; L Zhu; V P Torchilin
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-19       Impact factor: 15.336

7.  Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Olivier M Girard; Douglas Hanahan; Robert F Mattrey; Erkki Ruoslahti
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

8.  In vitro toxicity testing of nanoparticles in 3D cell culture.

Authors:  Jungwoo Lee; G Daniel Lilly; R Christopher Doty; Paul Podsiadlo; Nicholas A Kotov
Journal:  Small       Date:  2009-05       Impact factor: 13.281

9.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

Review 10.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

View more
  16 in total

1.  Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window.

Authors:  Fei Zhu; Wendong Yao; Yanjun Huang; Yanhong Chen; Zeng Wang; Xinjun Cai
Journal:  Ann Transl Med       Date:  2022-05

2.  Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells.

Authors:  Jessica Pullan; Kaitlin Dailey; Sangeeta Bhallamudi; Li Feng; Lina Alhalhooly; Jamie Froberg; Jenna Osborn; Kausik Sarkar; Todd Molden; Venkatachalem Sathish; Yongki Choi; Amanda Brooks; Sanku Mallik
Journal:  ACS Appl Bio Mater       Date:  2022-04-13

3.  Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells.

Authors:  Kevin O Affram; Taylor Smith; Edward Ofori; Sunil Krishnan; Patrick Underwood; Jose G Trevino; Edward Agyare
Journal:  J Drug Deliv Sci Technol       Date:  2019-11-08       Impact factor: 3.981

4.  Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.

Authors:  Babak Mamnoon; Jagadish Loganathan; Matthew I Confeld; Nimesha De Fonseka; Li Feng; Jamie Froberg; Yongki Choi; Daniel M Tuvin; Venkatachalem Sathish; Sanku Mallik
Journal:  ACS Appl Bio Mater       Date:  2020-12-23

Review 5.  Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs.

Authors:  Dirk van den Brand; Leon F Massuger; Roland Brock; Wouter P R Verdurmen
Journal:  Bioconjug Chem       Date:  2017-02-17       Impact factor: 4.774

Review 6.  Overcoming Hurdles in Nanoparticle Clinical Translation: The Influence of Experimental Design and Surface Modification.

Authors:  Jacob W Shreffler; Jessica E Pullan; Kaitlin M Dailey; Sanku Mallik; Amanda E Brooks
Journal:  Int J Mol Sci       Date:  2019-11-30       Impact factor: 5.923

Review 7.  From 2D to 3D Cancer Cell Models-The Enigmas of Drug Delivery Research.

Authors:  Indra Van Zundert; Beatrice Fortuni; Susana Rocha
Journal:  Nanomaterials (Basel)       Date:  2020-11-11       Impact factor: 5.076

8.  CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3.

Authors:  Xiaoxin Jin; Lifeng Cai; Changfa Wang; Xiaofeng Deng; Shengen Yi; Zhao Lei; Qiangsheng Xiao; Hongbo Xu; Hongwu Luo; Jichun Sun
Journal:  Cell Death Dis       Date:  2018-02-23       Impact factor: 8.469

Review 9.  Functional Nanoparticles for Tumor Penetration of Therapeutics.

Authors:  Yu-Lin Su; Shang-Hsiu Hu
Journal:  Pharmaceutics       Date:  2018-10-18       Impact factor: 6.321

Review 10.  Critical considerations for targeting colorectal liver metastases with nanotechnology.

Authors:  Usman Arshad; Paul A Sutton; Marianne B Ashford; Kevin E Treacher; Neill J Liptrott; Steve P Rannard; Christopher E Goldring; Andrew Owen
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.